{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    7,
    8,
    9,
    10,
    13,
    14,
    15,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "Upadacitinib 30 mg QD",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Subjects receive upadacitinib 30 mg once daily monotherapy. Note: Starting with Amendment 5, all subjects in this arm transition to open-label 15 mg QD."
      },
      {
        "id": "arm_2",
        "name": "Upadacitinib 15 mg QD",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Subjects receive upadacitinib 15 mg once daily monotherapy."
      },
      {
        "id": "arm_3",
        "name": "MTX to Upadacitinib 30 mg QD",
        "type": {
          "code": "Active Comparator Arm",
          "codeSystem": "USDM",
          "decode": "Active Comparator Arm"
        },
        "instanceType": "StudyArm",
        "description": "Subjects receive blinded Methotrexate (MTX) in Period 1, then switch to Upadacitinib 30 mg QD in Period 2."
      },
      {
        "id": "arm_4",
        "name": "MTX to Upadacitinib 15 mg QD",
        "type": {
          "code": "Active Comparator Arm",
          "codeSystem": "USDM",
          "decode": "Active Comparator Arm"
        },
        "instanceType": "StudyArm",
        "description": "Subjects receive blinded Methotrexate (MTX) in Period 1, then switch to Upadacitinib 15 mg QD in Period 2."
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_2",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_5"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_2",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_6"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_7",
        "armId": "arm_2",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_7"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_8",
        "armId": "arm_2",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_8"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_9",
        "armId": "arm_3",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_9"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_10",
        "armId": "arm_3",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_10"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_11",
        "armId": "arm_3",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_11"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_12",
        "armId": "arm_3",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_12"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_13",
        "armId": "arm_4",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_13"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_14",
        "armId": "arm_4",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_14"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_15",
        "armId": "arm_4",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_15"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_16",
        "armId": "arm_4",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_16"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "Upadacitinib 30 mg QD - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Upadacitinib 30 mg QD during Screening"
      },
      {
        "id": "elem_2",
        "name": "Upadacitinib 30 mg QD - Period 1",
        "instanceType": "StudyElement",
        "description": "Treatment period for Upadacitinib 30 mg QD during Period 1"
      },
      {
        "id": "elem_3",
        "name": "Upadacitinib 30 mg QD - Period 2",
        "instanceType": "StudyElement",
        "description": "Treatment period for Upadacitinib 30 mg QD during Period 2"
      },
      {
        "id": "elem_4",
        "name": "Upadacitinib 30 mg QD - Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Upadacitinib 30 mg QD during Follow-up"
      },
      {
        "id": "elem_5",
        "name": "Upadacitinib 15 mg QD - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Upadacitinib 15 mg QD during Screening"
      },
      {
        "id": "elem_6",
        "name": "Upadacitinib 15 mg QD - Period 1",
        "instanceType": "StudyElement",
        "description": "Treatment period for Upadacitinib 15 mg QD during Period 1"
      },
      {
        "id": "elem_7",
        "name": "Upadacitinib 15 mg QD - Period 2",
        "instanceType": "StudyElement",
        "description": "Treatment period for Upadacitinib 15 mg QD during Period 2"
      },
      {
        "id": "elem_8",
        "name": "Upadacitinib 15 mg QD - Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Upadacitinib 15 mg QD during Follow-up"
      },
      {
        "id": "elem_9",
        "name": "MTX to Upadacitinib 30 mg QD - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for MTX to Upadacitinib 30 mg QD during Screening"
      },
      {
        "id": "elem_10",
        "name": "MTX to Upadacitinib 30 mg QD - Period 1",
        "instanceType": "StudyElement",
        "description": "Treatment period for MTX to Upadacitinib 30 mg QD during Period 1"
      },
      {
        "id": "elem_11",
        "name": "MTX to Upadacitinib 30 mg QD - Period 2",
        "instanceType": "StudyElement",
        "description": "Treatment period for MTX to Upadacitinib 30 mg QD during Period 2"
      },
      {
        "id": "elem_12",
        "name": "MTX to Upadacitinib 30 mg QD - Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for MTX to Upadacitinib 30 mg QD during Follow-up"
      },
      {
        "id": "elem_13",
        "name": "MTX to Upadacitinib 15 mg QD - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for MTX to Upadacitinib 15 mg QD during Screening"
      },
      {
        "id": "elem_14",
        "name": "MTX to Upadacitinib 15 mg QD - Period 1",
        "instanceType": "StudyElement",
        "description": "Treatment period for MTX to Upadacitinib 15 mg QD during Period 1"
      },
      {
        "id": "elem_15",
        "name": "MTX to Upadacitinib 15 mg QD - Period 2",
        "instanceType": "StudyElement",
        "description": "Treatment period for MTX to Upadacitinib 15 mg QD during Period 2"
      },
      {
        "id": "elem_16",
        "name": "MTX to Upadacitinib 15 mg QD - Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for MTX to Upadacitinib 15 mg QD during Follow-up"
      }
    ],
    "summary": {
      "armCount": 4,
      "cellCount": 16,
      "cohortCount": 0,
      "elementCount": 16
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Double Blind",
        "codeSystem": "USDM",
        "decode": "Double Blind"
      },
      "maskedRoles": [
        "Subject",
        "Investigator"
      ],
      "randomizationType": {
        "code": "Randomized",
        "codeSystem": "USDM",
        "decode": "Randomized"
      },
      "allocationRatio": {
        "ratio": "2:2:1:1"
      },
      "controlType": {
        "code": "Active Control",
        "codeSystem": "USDM",
        "decode": "Active Control"
      },
      "armIds": [
        "arm_1",
        "arm_2",
        "arm_3",
        "arm_4"
      ],
      "therapeuticAreas": [
        "Rheumatology"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Double Blind",
        "maskedRoles": [
          "Subject",
          "Investigator"
        ]
      },
      "randomization": {
        "type": "Randomized",
        "allocationRatio": "2:2:1:1",
        "stratificationFactors": []
      },
      "controlType": "Active Control",
      "therapeuticAreas": [
        "Rheumatology"
      ]
    },
    "arms": [
      {
        "name": "Upadacitinib 30 mg QD",
        "type": "Experimental Arm",
        "description": "Subjects receive upadacitinib 30 mg once daily monotherapy. Note: Starting with Amendment 5, all subjects in this arm transition to open-label 15 mg QD.",
        "isTitration": false
      },
      {
        "name": "Upadacitinib 15 mg QD",
        "type": "Experimental Arm",
        "description": "Subjects receive upadacitinib 15 mg once daily monotherapy.",
        "isTitration": false
      },
      {
        "name": "MTX to Upadacitinib 30 mg QD",
        "type": "Active Comparator",
        "description": "Subjects receive blinded Methotrexate (MTX) in Period 1, then switch to Upadacitinib 30 mg QD in Period 2.",
        "isTitration": false
      },
      {
        "name": "MTX to Upadacitinib 15 mg QD",
        "type": "Active Comparator",
        "description": "Subjects receive blinded Methotrexate (MTX) in Period 1, then switch to Upadacitinib 15 mg QD in Period 2.",
        "isTitration": false
      }
    ],
    "cohorts": [],
    "epochs": [
      {
        "name": "Screening",
        "description": "35-day screening period"
      },
      {
        "name": "Period 1",
        "description": "14-week randomized, double-blind, parallel-group, controlled treatment period"
      },
      {
        "name": "Period 2",
        "description": "246-week blinded long-term extension period (converted to open-label 15mg QD under Amendment 5)"
      },
      {
        "name": "Follow-up",
        "description": "30-day follow-up visit"
      }
    ]
  }
}